INTELLIA THERAPEUTICS ($NTLA) posted quarterly earnings results for Q4 2025 on Thursday, February 26th. The company reported earnings of -$0.83 per share, beating estimates of -$0.97 by $0.14. The company also reported revenue of $23,020,000, beating estimates of $13,041,720 by $9,978,280.
You can see Quiver Quantitative's $NTLA stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
INTELLIA THERAPEUTICS Insider Trading Activity
INTELLIA THERAPEUTICS insiders have traded $NTLA stock on the open market 13 times in the past 6 months. Of those trades, 1 have been purchases and 12 have been sales.
Here’s a breakdown of recent trading of $NTLA stock by insiders over the last 6 months:
- FRED E COHEN purchased 150,000 shares for an estimated $1,402,500
- JOHN M LEONARD (President and CEO) has made 0 purchases and 4 sales selling 122,292 shares for an estimated $1,150,869.
- DAVID LEBWOHL (EVP, Chief Medical Officer) sold 11,903 shares for an estimated $109,626
- JAMES BASTA (EVP, General Counsel) sold 10,397 shares for an estimated $95,756
- ELIANA CLARK (EVP, Chief Technical Officer) sold 9,515 shares for an estimated $87,633
- BIRGIT C SCHULTES (EVP, Chief Scientific Officer) has made 0 purchases and 2 sales selling 8,539 shares for an estimated $78,897.
- MICHAEL P DUBE (VP, Chief Accounting Officer) has made 0 purchases and 2 sales selling 4,860 shares for an estimated $60,046.
- EDWARD J III DULAC (EVP, Chief Financial Officer) sold 6,379 shares for an estimated $58,750
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
INTELLIA THERAPEUTICS Hedge Fund Activity
We have seen 162 institutional investors add shares of INTELLIA THERAPEUTICS stock to their portfolio, and 162 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- CONTRARIUS GROUP HOLDINGS LTD removed 5,175,456 shares (-87.9%) from their portfolio in Q4 2025, for an estimated $46,527,349
- MORGAN STANLEY removed 3,694,724 shares (-61.3%) from their portfolio in Q4 2025, for an estimated $33,215,568
- D. E. SHAW & CO., INC. added 3,102,664 shares (+139.2%) to their portfolio in Q4 2025, for an estimated $27,892,949
- GOLDMAN SACHS GROUP INC removed 2,823,058 shares (-66.0%) from their portfolio in Q4 2025, for an estimated $25,379,291
- BAKER BROS. ADVISORS LP removed 2,746,674 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $24,692,599
- ARK INVESTMENT MANAGEMENT LLC added 2,288,146 shares (+19.2%) to their portfolio in Q4 2025, for an estimated $20,570,432
- VANGUARD GROUP INC added 1,965,181 shares (+17.8%) to their portfolio in Q4 2025, for an estimated $17,666,977
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
INTELLIA THERAPEUTICS Analyst Ratings
Wall Street analysts have issued reports on $NTLA in the last several months. We have seen 7 firms issue buy ratings on the stock, and 1 firms issue sell ratings.
Here are some recent analyst ratings:
- Truist Securities issued a "Buy" rating on 11/10/2025
- HC Wainwright & Co. issued a "Buy" rating on 11/10/2025
- JP Morgan issued a "Underweight" rating on 11/07/2025
- Citizens issued a "Market Outperform" rating on 11/07/2025
- Chardan Capital issued a "Buy" rating on 11/07/2025
- Barclays issued a "Overweight" rating on 11/07/2025
- JMP Securities issued a "Market Outperform" rating on 10/28/2025
To track analyst ratings and price targets for INTELLIA THERAPEUTICS, check out Quiver Quantitative's $NTLA forecast page.
INTELLIA THERAPEUTICS Price Targets
Multiple analysts have issued price targets for $NTLA recently. We have seen 13 analysts offer price targets for $NTLA in the last 6 months, with a median target of $14.0.
Here are some recent targets:
- Mitchell S. Kapoor from HC Wainwright & Co. set a target price of $25.0 on 01/28/2026
- Jonathan Miller from Evercore ISI Group set a target price of $8.0 on 11/11/2025
- Joon Lee from Truist Securities set a target price of $14.0 on 11/10/2025
- Gena Wang from Barclays set a target price of $14.0 on 11/07/2025
- Geulah Livshits from Chardan Capital set a target price of $26.0 on 11/07/2025
- Yanan Zhu from Wells Fargo set a target price of $12.0 on 11/07/2025
- Luca Issi from RBC Capital set a target price of $9.0 on 11/07/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
